You searched for cnsp - Page 14 of 21

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Business Update, Progress on Driving Berubicin’s Development

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today provided a business update. Among the highlights, the company reported on its continued progress to drive Berubicin towards commercialization for the treatment of glioblastoma multiforme (“GBM”). “In the … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Business Update, Progress on Driving Berubicin’s Development”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives FDA Fast Track Status for Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that the U.S. Food and Drug Administration granted Fast Track Designation for Berubicin, the company’s lead investigational drug. The status was received for the company’s evaluation of Berubicin … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives FDA Fast Track Status for Berubicin Study”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP), WPD Pharmaceuticals to Soon Recruit Patients for Combined Berubicin Clinical Studies

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, sublicenses the compound Berubicin to WPD Pharmaceuticals for 30 countries mainly in Europe and Asia. WPD, a clinical-stage pharmaceutical company, today provided an update on its Berubicin drug candidate … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP), WPD Pharmaceuticals to Soon Recruit Patients for Combined Berubicin Clinical Studies”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Committed to Driving Novel Treatments Forward with Key Focus on Berubicin

CNS Pharmaceuticals’ (NASDAQ: CNSP) lead drug candidate, Berubicin, is a novel anthracycline, the first of which to appear capable of crossing the blood-brain barrier based on limited clinical data. The company is currently developing Berubicin in the treatment of several serious brain and central nervous system oncological indications. CNS is set to commence patient enrollment … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Committed to Driving Novel Treatments Forward with Key Focus on Berubicin”

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Gains Inclusion on Russell 2000 Index as Brain Cancer Trial Enrollment Advances

Brain cancer drug developer CNS Pharmaceuticals is actively enrolling patients for a potentially pivotal Phase 2 trial of the company’s lead drug candidate, Berubicin, a promising candidate for treating a devastating condition CNS’s focus has been on developing a means of combating glioblastoma, a fatal, generally incurable class of brain cancers that are aggressive and … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Gains Inclusion on Russell 2000 Index as Brain Cancer Trial Enrollment Advances”

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Reports First Quarter Financials; Anticipates Improved Patient Outcomes with Berubicin

Company expects reporting on interim analysis for the first 18 patients of a Phase 2 multicenter clinical trial of Berubicin in adult GBM patients during the first half of 2022 One patient from the first Berubicin trial has survived cancer-free for 14 years, while two patients saw tumor reduction of up to 80 percent CNS … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Reports First Quarter Financials; Anticipates Improved Patient Outcomes with Berubicin”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set for Inclusion in Russell 2000 Index

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that the company will be added to the Russell 2000(R) Index, effective June 25, 2021, after the close of the U.S. equity markets. CNSP will be added following … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set for Inclusion in Russell 2000 Index”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Nears Dosing of Phase 2 Patients with Standout Anthracycline Therapy

CNS Pharmaceuticals (NASDAQ: CNSP) is focused on producing a treatment that improves on the effectiveness of established chemotherapy drug lomustine in increasing overall survival rates of glioblastoma multiforme (“GBM”) patients. GBM is an illness that is nearly 100% fatal in patients just over a year after diagnosis. CNS Pharmaceuticals’ lead drug candidate, Berubicin, has been … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Nears Dosing of Phase 2 Patients with Standout Anthracycline Therapy”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Study Promising Candidate in Phase 2 GBM Trial

CNS Pharmaceuticals (NASDAQ: CNSP) is on track to begin a potentially pivotal Phase 2 trial during the second quarter of 2021. This trial of CNSP’s lead drug candidate, Berubicin, in the treatment of glioblastoma multiforme (“GBM”) is currently planned to include up to 243 subjects, randomized 2:1 (162 Berubicin/81 Lomustine) with an interim analysis when … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Study Promising Candidate in Phase 2 GBM Trial”

GBM Brain Cancer Sorting Development Latest Bit of Good News for Patients as CNS Pharmaceuticals (NASDAQ: CNSP) Develops Drug Trial

Biopharmaceutical developer CNS Pharmaceuticals is working on ways to improve overall survivability for glioblastoma multiforme (“GBM”) brain cancer patients GBM is considered to be an incurable brain cancer that usually only leaves patients about 15 months to live once they are diagnosed, prompting research efforts to improve patients’ responses to therapeutic approaches A recent study … Continue reading “GBM Brain Cancer Sorting Development Latest Bit of Good News for Patients as CNS Pharmaceuticals (NASDAQ: CNSP) Develops Drug Trial”

Site Search

Company Search

Search Results for: cnsp